India is set to receive Russian Vaccine Sputnik V stocks in this quarter, between April and Jun, which was granted emergency use authorisation (EUA) earlier this week on Monday, 12 April reports Times of India.
After Covishield and Covaxin, Sputnik V became the third Covid-19 vaccine to be used in the country.
As part of its contract with the Russian Direct Investment Fund (RDIF), Hyderabad-based Dr Reddy’s Laboratories (DRL) is expected to receive around 250 million doses of Sputnik V.
DRL has received restricted emergency use permission to supply the vaccine in liquid form, so the company will have to arrange logistics to store and distribute the vaccine at lower temperatures of minus 18°C to minus 22°C, at which its safety and potency can be ensured.
The vaccine is slated to be available in larger quantities in the July-September quarter once the Indian companies that have tied up with RDIF begin manufacturing in the country.
RDIF has agreements with Gland Pharma, Stelis Biopharma, Hetero Biopharma, Panacea Biotec, Virchow Biotech, and Shilpa Medicare to manufacture 850 million doses of Sputnik V in India.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.